Načítá se...
Cell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthase
New agent development, mechanistic understanding, and combinatorial partnerships with known and novel modalities continue to be important in the study of pancreatic cancer and its improved treatment. In this study, known antimetabolite drugs such as gemcitabine (ribonucleotide reductase inhibitor) a...
Uloženo v:
| Vydáno v: | Onco Targets Ther |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4354452/ https://ncbi.nlm.nih.gov/pubmed/25767396 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S79647 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|